Department of Transportation Throws Out Complaint Against Southwest Airlines By Nut Allergy Sufferers

Key Takeaways

• DOT dismissed complaint, siding with Southwest.
• Pre‑boarding rule change stemmed from internal memo error.
• Southwest reinstated nut‑allergy pre‑boarding before complaint filed.
• DOT limited pre‑boarding requirement to nut allergies only.
• Southwest to stock EpiPens on flights starting 2024.

Summary

The U.S. Department of Transportation (DOT) dismissed a complaint by four allergy advocacy groups that claimed Southwest Airlines violated the Air Carrier Access Act by removing nut‑allergy passengers from pre‑boarding. Southwest had shifted those passengers to a later “extra time” boarding group in late 2022 but reversed the change before the complaint was lodged, citing an internal miscommunication. The DOT concluded that while nut allergies are a disability, the agency’s pre‑boarding rule applies only to nut‑allergy sufferers and does not automatically extend to other food allergies without formal rulemaking. Separately, Southwest agreed to begin carrying epinephrine auto‑injectors on its flights in 2024, addressing broader concerns about in‑flight anaphylaxis treatment.

Pulse Analysis

The Department of Transportation’s decision underscores how narrowly defined disability accommodations can shape airline operations. Since the 2019 DOT ruling, carriers have been required to offer pre‑boarding to passengers who self‑identify as having a disability, a category that includes severe nut allergies. By limiting the pre‑boarding mandate to nut‑allergy sufferers, the agency signals that any expansion to other food allergies will require a formal rulemaking process, preserving regulatory predictability for airlines while still protecting a recognized disability group.

Southwest Airlines’ internal memo in September 2022 mistakenly moved nut‑allergy passengers from the pre‑boarding queue to a later boarding group, prompting the advocacy groups’ complaint. The airline acted quickly, restoring the original policy before the DOT received the formal grievance, and the agency exercised “enforcement discretion” to forgo penalties. This episode illustrates how airlines must maintain rigorous internal compliance checks; even unintentional policy shifts can attract regulatory scrutiny and legal challenges, potentially affecting brand reputation and operational costs.

Beyond boarding procedures, the DOT’s handling of the case coincides with Southwest’s commitment to stock epinephrine auto‑injectors on all flights beginning in 2024. The move follows pressure from senators and consumer advocates who argue that current single‑dose vials are impractical for layperson use. By adopting EpiPens, Southwest not only enhances passenger safety but also positions itself ahead of potential future mandates that could require broader medical kit upgrades across the industry, influencing competitive dynamics and cost structures for U.S. carriers.